Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Mar 12, 2024 6:10am
105 Views
Post# 35927886

RE:BNN next week

RE:BNN next week
Interesting!

In the short-term, our results and financial situation will be significantly influenced by a couple things:

1) Will the MOH contracts continue coming in? This will significantly affect our growth rate in the short term.
2) I assume the final decision for the tax issue will be made soon (or this year, at least), just because it has already taken quite long. Winning this would be a nice bonus although I'm not counting on this at all. But either we will or we won't have $40M+ of extra cash around. This won't change the outlook of the business but getting an extra cash worth 8% or so of the market cap is always nice.

Both of those could go against us.

However, for the long term, we're in growing markets (both in terms of geography and product categories) with a team that knows what they're doing. The scale advantages are kicking in, we have growing products within the portfolio (including a few new launches), and the pipeline is nearing the point (< 1 year) where it starts producing a constant stream of new launches. Furthermore, as has always been the case, we have the balance sheet to take an advantage of new opportunities. At some point, they will find those opportunitites, but in the meantime, we have about 40% of our market cap in net cash, investments and financial assets that are not doing much for us in terms of our operational business. This is a weakness until it's a strength.
<< Previous
Bullboard Posts
Next >>